Similar Papers

Paper Title
Journal
Date
Author
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Constantine S Tam ... Andrew W Roberts
Blood | VOL. 128
Constantine S Tam, et. al.Constantine S Tam ... Andrew W Roberts
02 Dec 2016
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
Ekaterina Kim ... Jan A Burger
Blood | VOL. 134
Ekaterina Kim, et. al.Ekaterina Kim ... Jan A Burger
13 Nov 2019
The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors
Ekaterina Kim ... Jan A Burger
Blood | VOL. 130
Ekaterina Kim, et. al.Ekaterina Kim ... Jan A Burger
25 Jun 2021
Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study
Kerry A Rogers ... John C Byrd
Blood | VOL. 138
Kerry A Rogers, et. al.Kerry A Rogers ... John C Byrd
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
A novel therapy with a rational design for AML.
Maria L Amaya
Blood | VOL. 145
Maria L AmayaMaria L Amaya
30 Jan 2025
For how long has this problem been there?
Niccolò Bolli ... Matteo Claudio Da Vià
Blood | VOL. 145
Niccolò Bolli, et. al.Niccolò Bolli ... Matteo Claudio Da Vià
30 Jan 2025
Targeting CD47: many misses; hopeful for a hit.
Lindsay Wilde ... Margaret Kasner
Blood | VOL. 145
Lindsay Wilde, et. al.Lindsay Wilde ... Margaret Kasner
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.